Natenael B Semmineh1,2, Junzhong Xu1,3, Jack T Skinner1,3, Jingping Xie1, Hua Li1,2, Gregory Ayers4, C Chad Quarles1,2,3,5,6. 1. Institute of Imaging Science, Vanderbilt University, Nashville, Tennessee, USA. 2. Department of Physics and Astronomy, Vanderbilt University, Nashville, Tennessee, USA. 3. Department of Radiology and Radiological Sciences, Vanderbilt University, Nashville, Tennessee, USA. 4. Department of Biostatistics, Vanderbilt University, Nashville, Tennessee, USA. 5. Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee, USA. 6. Department of Cancer Biology, Vanderbilt University, Nashville, Tennessee, USA.
Abstract
PURPOSE: In brain tumor dynamic susceptibility contrast (DSC)-MRI studies, multiecho acquisition methods are used to quantify the dynamic changes in T1 and T2 * that occur when contrast agent (CA) extravasates. Such methods also enable the estimation of the effective tissue CA transverse relaxivity. The goal of this study was to evaluate the sensitivity of the transverse relaxivity at tracer equilibrium (TRATE) to tumor cytoarchitecture. METHODS: Computational and in vitro studies were used to evaluate the biophysical basis of TRATE. In 9L, C6, and human brain tumors, TRATE, the apparent diffusion coefficient (ADC), the CA transfer constant (K(trans) ), the extravascular extracellular volume fraction (ve ), and histological data were compared. RESULTS: Simulations and in vitro results indicate that TRATE is highly sensitive to variations in cellular properties such as cell size and density. The histologic cell density and TRATE values were significantly higher in 9L tumors as compared to C6 tumors. In animal and human tumors, a voxel-wise comparison of TRATE with ADC, ve , and K(trans) maps showed low spatial correlation. CONCLUSION: The assessment of TRATE is clinically feasible and its sensitivity to tissue cytoarchitectural features not present in other imaging methods indicate that it could potentially serve as a unique structural signature or "trait" of cancer.
PURPOSE: In brain tumor dynamic susceptibility contrast (DSC)-MRI studies, multiecho acquisition methods are used to quantify the dynamic changes in T1 and T2 * that occur when contrast agent (CA) extravasates. Such methods also enable the estimation of the effective tissue CA transverse relaxivity. The goal of this study was to evaluate the sensitivity of the transverse relaxivity at tracer equilibrium (TRATE) to tumor cytoarchitecture. METHODS: Computational and in vitro studies were used to evaluate the biophysical basis of TRATE. In 9L, C6, and humanbrain tumors, TRATE, the apparent diffusion coefficient (ADC), the CA transfer constant (K(trans) ), the extravascular extracellular volume fraction (ve ), and histological data were compared. RESULTS: Simulations and in vitro results indicate that TRATE is highly sensitive to variations in cellular properties such as cell size and density. The histologic cell density and TRATE values were significantly higher in 9L tumors as compared to C6 tumors. In animal and humantumors, a voxel-wise comparison of TRATE with ADC, ve , and K(trans) maps showed low spatial correlation. CONCLUSION: The assessment of TRATE is clinically feasible and its sensitivity to tissue cytoarchitectural features not present in other imaging methods indicate that it could potentially serve as a unique structural signature or "trait" of cancer.
Authors: H J Aronen; F S Pardo; D N Kennedy; J W Belliveau; S D Packard; D W Hsu; F H Hochberg; A J Fischman; B R Rosen Journal: Clin Cancer Res Date: 2000-06 Impact factor: 12.531
Authors: L S Hu; H Yoon; J M Eschbacher; L C Baxter; A C Dueck; A Nespodzany; K A Smith; P Nakaji; Y Xu; L Wang; J P Karis; A J Hawkins-Daarud; K W Singleton; P R Jackson; B J Anderies; B R Bendok; R S Zimmerman; C Quarles; A B Porter-Umphrey; M M Mrugala; A Sharma; J M Hoxworth; M G Sattur; N Sanai; P E Koulemberis; C Krishna; J R Mitchell; T Wu; N L Tran; K R Swanson; J Li Journal: AJNR Am J Neuroradiol Date: 2019-02-28 Impact factor: 3.825
Authors: Ashley M Stokes; Natenael B Semmineh; Ashley Nespodzany; Laura C Bell; C Chad Quarles Journal: Magn Reson Med Date: 2019-08-09 Impact factor: 4.668
Authors: L C Bell; M D Does; A M Stokes; L C Baxter; K M Schmainda; A C Dueck; C C Quarles Journal: AJNR Am J Neuroradiol Date: 2017-07-06 Impact factor: 3.825
Authors: Leland S Hu; Shuluo Ning; Jennifer M Eschbacher; Leslie C Baxter; Nathan Gaw; Sara Ranjbar; Jonathan Plasencia; Amylou C Dueck; Sen Peng; Kris A Smith; Peter Nakaji; John P Karis; C Chad Quarles; Teresa Wu; Joseph C Loftus; Robert B Jenkins; Hugues Sicotte; Thomas M Kollmeyer; Brian P O'Neill; William Elmquist; Joseph M Hoxworth; David Frakes; Jann Sarkaria; Kristin R Swanson; Nhan L Tran; Jing Li; J Ross Mitchell Journal: Neuro Oncol Date: 2016-08-08 Impact factor: 12.300
Authors: Jerrold L Boxerman; Chad C Quarles; Leland S Hu; Bradley J Erickson; Elizabeth R Gerstner; Marion Smits; Timothy J Kaufmann; Daniel P Barboriak; Raymond H Huang; Wolfgang Wick; Michael Weller; Evanthia Galanis; Jayashree Kalpathy-Cramer; Lalitha Shankar; Paula Jacobs; Caroline Chung; Martin J van den Bent; Susan Chang; W K Al Yung; Timothy F Cloughesy; Patrick Y Wen; Mark R Gilbert; Bruce R Rosen; Benjamin M Ellingson; Kathleen M Schmainda Journal: Neuro Oncol Date: 2020-09-29 Impact factor: 12.300
Authors: Leland S Hu; Shuluo Ning; Jennifer M Eschbacher; Nathan Gaw; Amylou C Dueck; Kris A Smith; Peter Nakaji; Jonathan Plasencia; Sara Ranjbar; Stephen J Price; Nhan Tran; Joseph Loftus; Robert Jenkins; Brian P O'Neill; William Elmquist; Leslie C Baxter; Fei Gao; David Frakes; John P Karis; Christine Zwart; Kristin R Swanson; Jann Sarkaria; Teresa Wu; J Ross Mitchell; Jing Li Journal: PLoS One Date: 2015-11-24 Impact factor: 3.240